Literature DB >> 29507092

Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration.

Damien Bonnard1,2, Erwann Le Rouzic3, Sylvia Eiler4, Céline Amadori3,5, Igor Orlov4, Jean-Michel Bruneau3, Julie Brias3, Julien Barbion3, Francis Chevreuil3, Danièle Spehner4, Sophie Chasset3, Benoit Ledoussal3, François Moreau3, Ali Saïb2, Bruno P Klaholz4, Stéphane Emiliani5, Marc Ruff6, Alessia Zamborlini7, Richard Benarous8.   

Abstract

Recently, a new class of HIV-1 integrase (IN) inhibitors with a dual mode of action, called IN-LEDGF/p75 allosteric inhibitors (INLAIs), was described. Designed to interfere with the IN-LEDGF/p75 interaction during viral integration, unexpectedly, their major impact was on virus maturation. This activity has been linked to induction of aberrant IN multimerization, whereas inhibition of the IN-LEDGF/p75 interaction accounts for weaker antiretroviral effect at integration. Because these dual activities result from INLAI binding to IN at a single binding site, we expected that these activities co-evolved together, driven by the affinity for IN. Using an original INLAI, MUT-A, and its activity on an Ala-125 (A125) IN variant, we found that these two activities on A125-IN can be fully dissociated: MUT-A-induced IN multimerization and the formation of eccentric condensates in viral particles, which are responsible for inhibition of virus maturation, were lost, whereas inhibition of the IN-LEDGF/p75 interaction and consequently integration was fully retained. Hence, the mere binding of INLAI to A125 IN is insufficient to promote the conformational changes of IN required for aberrant multimerization. By analyzing the X-ray structures of MUT-A bound to the IN catalytic core domain (CCD) with or without the Ala-125 polymorphism, we discovered that the loss of IN multimerization is due to stabilization of the A125-IN variant CCD dimer, highlighting the importance of the CCD dimerization energy for IN multimerization. Our study reveals that affinity for the LEDGF/p75-binding pocket is not sufficient to induce INLAI-dependent IN multimerization and the associated inhibition of viral maturation.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  INLAI; LEDGF; allosteric regulation; crystal structure; human immunodeficiency virus (HIV); inhibitor; integrase; multimerization; polymorphism; viral replication

Mesh:

Substances:

Year:  2018        PMID: 29507092      PMCID: PMC5912470          DOI: 10.1074/jbc.M117.816793

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  The stoichiometry of Gag protein in HIV-1.

Authors:  John A G Briggs; Martha N Simon; Ingolf Gross; Hans-Georg Kräusslich; Stephen D Fuller; Volker M Vogt; Marc C Johnson
Journal:  Nat Struct Mol Biol       Date:  2004-06-20       Impact factor: 15.369

2.  Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Authors:  Lee D Fader; Eric Malenfant; Mathieu Parisien; Rebekah Carson; François Bilodeau; Serge Landry; Marc Pesant; Christian Brochu; Sébastien Morin; Catherine Chabot; Ted Halmos; Yves Bousquet; Murray D Bailey; Stephen H Kawai; René Coulombe; Steven LaPlante; Araz Jakalian; Punit K Bhardwaj; Dominik Wernic; Patricia Schroeder; Ma'an Amad; Paul Edwards; Michel Garneau; Jianmin Duan; Michael Cordingley; Richard Bethell; Stephen W Mason; Michael Bös; Pierre Bonneau; Marc-André Poupart; Anne-Marie Faucher; Bruno Simoneau; Craig Fenwick; Christiane Yoakim; Youla Tsantrizos
Journal:  ACS Med Chem Lett       Date:  2014-01-22       Impact factor: 4.345

3.  Stock-based detection of protein oligomeric states in jsPISA.

Authors:  Eugene Krissinel
Journal:  Nucleic Acids Res       Date:  2015-04-23       Impact factor: 16.971

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor.

Authors:  Fabrice Michel; Corinne Crucifix; Florence Granger; Sylvia Eiler; Jean-François Mouscadet; Sergei Korolev; Julia Agapkina; Rustam Ziganshin; Marina Gottikh; Alexis Nazabal; Stéphane Emiliani; Richard Benarous; Dino Moras; Patrick Schultz; Marc Ruff
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

6.  Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.

Authors:  Max Lataillade; Jennifer Chiarella; Michael J Kozal
Journal:  Antivir Ther       Date:  2007

7.  The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency.

Authors:  Lei Feng; Venkatasubramanian Dharmarajan; Erik Serrao; Ashley Hoyte; Ross C Larue; Alison Slaughter; Amit Sharma; Matthew R Plumb; Jacques J Kessl; James R Fuchs; Frederic D Bushman; Alan N Engelman; Patrick R Griffin; Mamuka Kvaratskhelia
Journal:  ACS Chem Biol       Date:  2016-03-02       Impact factor: 5.100

8.  LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions.

Authors:  Belete Ayele Desimmie; Rik Schrijvers; Jonas Demeulemeester; Doortje Borrenberghs; Caroline Weydert; Wannes Thys; Sofie Vets; Barbara Van Remoortel; Johan Hofkens; Jan De Rijck; Jelle Hendrix; Norbert Bannert; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  Retrovirology       Date:  2013-05-30       Impact factor: 4.602

9.  The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Authors:  Melissa Wares; Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Mark A Wainberg
Journal:  Retrovirology       Date:  2014-01-17       Impact factor: 4.602

10.  The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome.

Authors:  Nikki van Bel; Yme van der Velden; Damien Bonnard; Erwann Le Rouzic; Atze T Das; Richard Benarous; Ben Berkhout
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

View more
  17 in total

Review 1.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

2.  Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.

Authors:  Kyle Parcella; Tao Wang; Kyle Eastman; Zhongxing Zhang; Zhiwei Yin; Manoj Patel; Yong Tu; Barbara Zhizhen Zheng; Michael A Walker; Mark G Saulnier; David Frennesson; Michael Bowsher; Eric Gillis; Kevin Peese; Makonen Belema; Christopher Cianci; Ira B Dicker; Brian McAuliffe; Bo Ding; Paul Falk; Jean Simmermacher; Dawn D Parker; Prasanna Sivaprakasam; Kevin Kish; Hal Lewis; Umesh Hanumegowda; Susan Jenkins; John F Kadow; Mark Krystal; Nicholas A Meanwell; B Narasimhulu Naidu
Journal:  ACS Med Chem Lett       Date:  2022-05-09       Impact factor: 4.632

Review 3.  Structure and function of retroviral integrase.

Authors:  Goedele N Maertens; Alan N Engelman; Peter Cherepanov
Journal:  Nat Rev Microbiol       Date:  2021-07-09       Impact factor: 60.633

4.  Computational design of small molecular modulators of protein-protein interactions with a novel thermodynamic cycle: Allosteric inhibitors of HIV-1 integrase.

Authors:  Qinfang Sun; Vijayan S K Ramaswamy; Ronald Levy; Nanjie Deng
Journal:  Protein Sci       Date:  2020-12-05       Impact factor: 6.993

5.  Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602.

Authors:  Yoshitsugu Ohata; Mitsunori Tomonaga; Yasuo Watanabe; Keiko Tomura; Koji Kimura; Tatsuo Akaki; Kaoru Adachi; Eiichi N Kodama; Yuji Matsuzaki; Hironori Hayashi
Journal:  J Virol       Date:  2022-01-19       Impact factor: 6.549

Review 6.  Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase.

Authors:  Eungi Choi; Jayapal Reddy Mallareddy; Dai Lu; Srikanth Kolluru
Journal:  Future Sci OA       Date:  2018-09-06

7.  Impact of LEDGIN treatment during virus production on residual HIV-1 transcription.

Authors:  Gerlinde Vansant; Lenard S Vranckx; Irena Zurnic; Dominique Van Looveren; Paulien Van de Velde; Christopher Nobles; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  Retrovirology       Date:  2019-04-02       Impact factor: 4.602

8.  A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site.

Authors:  Tatsuya Maehigashi; Seohyun Ahn; Uk-Il Kim; Jared Lindenberger; Adrian Oo; Pratibha C Koneru; Bijan Mahboubi; Alan N Engelman; Mamuka Kvaratskhelia; Kyungjin Kim; Baek Kim
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

9.  Synthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors.

Authors:  Nicholas G Jentsch; Alison P Hart; Jared D Hume; Jian Sun; Kaitlin A McNeely; Chiyang Lama; Julie A Pigza; Matthew G Donahue; Jacques J Kessl
Journal:  ACS Med Chem Lett       Date:  2018-09-14       Impact factor: 4.632

10.  Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis.

Authors:  Jennifer L Elliott; Jenna E Eschbach; Pratibha C Koneru; Wen Li; Maritza Puray-Chavez; Dana Townsend; Dana Q Lawson; Alan N Engelman; Mamuka Kvaratskhelia; Sebla B Kutluay
Journal:  Elife       Date:  2020-09-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.